

**tobramycin 300mg/4ml nebuliser solution  
(Bramitob<sup>®</sup>)**

**(No. 314/06)**

**Trinity Chiesi Pharmaceuticals Ltd**

New Product

**In Confidence**

**8 September 2006** (Issued February 2009)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**tobramycin 300mg/4ml nebuliser solution (Bramitob<sup>®</sup>)** is accepted for use in NHS Scotland for the management of chronic pulmonary infection due to *Pseudomonas aeruginosa* in patients with cystic fibrosis aged 6 years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial agents. This preparation offers an alternative to an existing nebuliser solution at a lower cost per dose.

Advice must be treated in strict confidence until published in the public domain on the SMC website ([www.scottishmedicines.org.uk](http://www.scottishmedicines.org.uk)) on **09 March 2009**.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 16 January 2009 and costs from eVadis on 21 January 2009.*

**Chairman,  
Scottish Medicines Consortium**

*Published 09 March 2009*